Human C1-Esterase Inhibitor Csl Behring (C1 Esterase Inhibitor (Human))

Human C1‑Esterase Inhibitor Csl Behring is indicated for the management of hereditary angioedema (HAE) in patients with documented C1‑esterase inhibitor deficiency. It is used to:

• Prevent acute swelling attacks in HAE patients.
• Reduce frequency of HAE episodes when used prophylactically.
• Provide on‑demand treatment for breakthrough attacks.
• Serve as replacement therapy during surgical or dental procedures in HAE.

• Human C1‑esterase inhibitor replaces the deficient plasma protein that regulates the complement and contact systems. By restoring C1‑inhibitor activity, it blocks uncontrolled activation of plasma kallikrein and factor XIIa, thereby limiting generation of bradykinin and preventing excessive complement cascade activation that leads to vascular permeability and angioedema. The restored inhibition also stabilizes the C1 complex and reduces downstream inflammatory mediators, contributing to control of swelling episodes.

Adverse reactions reported with subcutaneous human C1‑esterase inhibitor are generally mild to moderate, but serious events can occur.

Common

• Injection site pain, erythema, or swelling.
• Headache.
• Nausea.
• Fatigue.
• Flu‑like symptoms.

Serious

• Anaphylaxis or severe hypersensitivity reactions.
• Thromboembolic events (e.g., deep‑vein thrombosis, pulmonary embolism).
• Acute renal impairment.
• Severe hypotension.
• Disseminated intravascular coagulation (rare).

Before initiating therapy, clinicians should evaluate patient history and monitor for conditions that may increase risk of complications.

• Assess for known hypersensitivity to C1‑esterase inhibitor or any component of the formulation.
• Use caution in patients with a history of thromboembolic disease.
• Monitor renal function in patients with pre‑existing kidney impairment.
• Consider dose adjustment or close observation during pregnancy or lactation, as safety data are limited.
• Evaluate for concurrent use of other plasma‑derived products that may affect complement activity.
• Avoid use in patients with active infection without appropriate treatment.

Human C1‑esterase inhibitor may interact with other agents that influence coagulation, complement pathways, or immune responses.

Avoid

• Concomitant use of other plasma‑derived C1‑inhibitor concentrates without medical justification.
• Concurrent administration of pro‑coagulant agents (e.g., high‑dose estrogen therapy) that increase thrombosis risk.
• Live vaccines during active treatment without physician oversight.

Use with caution

• Antifibrinolytics (e.g., tranexamic acid) may augment hemostatic effects.
• ACE inhibitors may increase risk of angioedema; monitor closely.
• Immunosuppressants may alter response to replacement therapy.
• Hormonal contraceptives; assess thrombotic risk.
• Other immunomodulatory drugs that could affect complement activity.